CL2023000362A1 - Métodos de tratamiento de la trombocitemia - Google Patents
Métodos de tratamiento de la trombocitemiaInfo
- Publication number
- CL2023000362A1 CL2023000362A1 CL2023000362A CL2023000362A CL2023000362A1 CL 2023000362 A1 CL2023000362 A1 CL 2023000362A1 CL 2023000362 A CL2023000362 A CL 2023000362A CL 2023000362 A CL2023000362 A CL 2023000362A CL 2023000362 A1 CL2023000362 A1 CL 2023000362A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- thrombocythemia
- treating
- treating thrombocythemia
- isoxazolo
- Prior art date
Links
- 208000005485 Thrombocytosis Diseases 0.000 title abstract 2
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating thrombocythemia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060723P | 2020-08-04 | 2020-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000362A1 true CL2023000362A1 (es) | 2024-01-19 |
Family
ID=77519789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000362A CL2023000362A1 (es) | 2020-08-04 | 2023-02-03 | Métodos de tratamiento de la trombocitemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230302010A1 (es) |
| EP (1) | EP4192470A1 (es) |
| JP (1) | JP2023537715A (es) |
| KR (1) | KR20230048042A (es) |
| CN (1) | CN116367839A (es) |
| AU (1) | AU2021320151A1 (es) |
| BR (1) | BR112023002134A2 (es) |
| CA (1) | CA3188245A1 (es) |
| CL (1) | CL2023000362A1 (es) |
| IL (1) | IL300337A (es) |
| MX (1) | MX2023001552A (es) |
| WO (1) | WO2022031686A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
| MX2021006205A (es) * | 2018-11-27 | 2021-10-13 | Constellation Pharmaceuticals Inc | Metodos de tratamiento de trastornos mieloproliferativos. |
-
2021
- 2021-08-03 WO PCT/US2021/044318 patent/WO2022031686A1/en unknown
- 2021-08-03 US US18/019,634 patent/US20230302010A1/en active Pending
- 2021-08-03 AU AU2021320151A patent/AU2021320151A1/en active Pending
- 2021-08-03 MX MX2023001552A patent/MX2023001552A/es unknown
- 2021-08-03 EP EP21762216.6A patent/EP4192470A1/en active Pending
- 2021-08-03 JP JP2023507598A patent/JP2023537715A/ja active Pending
- 2021-08-03 BR BR112023002134A patent/BR112023002134A2/pt unknown
- 2021-08-03 CN CN202180065736.5A patent/CN116367839A/zh active Pending
- 2021-08-03 KR KR1020237004712A patent/KR20230048042A/ko unknown
- 2021-08-03 IL IL300337A patent/IL300337A/en unknown
- 2021-08-03 CA CA3188245A patent/CA3188245A1/en active Pending
-
2023
- 2023-02-03 CL CL2023000362A patent/CL2023000362A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023002134A2 (pt) | 2023-03-07 |
| JP2023537715A (ja) | 2023-09-05 |
| US20230302010A1 (en) | 2023-09-28 |
| KR20230048042A (ko) | 2023-04-10 |
| IL300337A (en) | 2023-04-01 |
| CN116367839A (zh) | 2023-06-30 |
| WO2022031686A1 (en) | 2022-02-10 |
| CA3188245A1 (en) | 2022-02-10 |
| MX2023001552A (es) | 2023-05-03 |
| AU2021320151A1 (en) | 2023-02-23 |
| EP4192470A1 (en) | 2023-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121997T1 (el) | Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου | |
| PH12021551180A1 (en) | Methods of treating myeloproliferative disorders | |
| MX2018000718A (es) | Macrociclos de diarilo quirales y usos de los mismos. | |
| PH12020551639A1 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| BR112018070304A2 (pt) | formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| CY1106606T1 (el) | Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv | |
| AR031152A1 (es) | Tratamientos nuevos para el sindrome de piernas inquietas | |
| DE60206028D1 (de) | Oxazolylpyrazol-derivate als kinase-inhibitoren | |
| MA53759A (fr) | Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication | |
| EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| WO2015195863A8 (en) | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide | |
| EA202191903A1 (ru) | Антипролиферативные соединения и вторые активные агенты для комбинированного применения | |
| CL2020003118A1 (es) | Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k. | |
| MX2021016149A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
| ES2324794T3 (es) | Imidazo(4,5-c)pyridine componente y metodo de tratamiento antiviral. | |
| PE20211818A1 (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal | |
| CL2023000362A1 (es) | Métodos de tratamiento de la trombocitemia | |
| AU2018260628A1 (en) | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | |
| BR112018074162A2 (pt) | composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica. | |
| EA202191489A1 (ru) | Способы лечения миелопролиферативных расстройств | |
| MX2019000159A (es) | Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa. | |
| MX2022016179A (es) | Compuestos y metodos para tratar infecciones fungicas. |